Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment. Havrilesky LJ, Lim S, Ehrisman JA, Lorenzo A, et al. Gynecol Oncol 2020 Jan 22. pii: S0090-8258(20)30070.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Havrilesky LJ, Lim S, Ehrisman JA, Lorenzo A, et al. Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment. Gynecol Oncol 2020 Jan 22. pii: S0090-8258(20)30070.
PMID: 31982178